We can’t show the full text here under this license.
Chiglitazar improves hormone-induced polycystic ovary syndrome in rats
Updated
Abstract
Chiglitazar improved ovulation in rats with (PCOS) and may offer a novel therapeutic strategy.
- Chiglitazar and pioglitazone both alleviated PCOS symptoms, with chiglitazar showing a greater impact on lipid levels and weight gain.
- Both treatments resulted in notable recovery in oxygen consumption and carbon dioxide output, alongside significant improvements in glucose tolerance and .
- Chiglitazar treatment led to increased levels of adiponectin and decreased levels of serum insulin, androgens, luteinizing hormone, and the luteinizing hormone to follicle-stimulating hormone ratio.
- In the chiglitazar-treated group, significant decreases were observed in triglycerides, free fatty acids, and atherosclerosis index compared to the PCOS model group.
- Enhanced ovarian health was indicated by increased granulosa cells and healthy follicles, along with elevated ovarian steroidogenic enzymes.
Simplified
Key numbers
50%
Decrease in Insulin Level
Reduction in serum insulin concentration in the DHEA + CHI group compared to the DHEA group.
Notable increase
Increase in Adiponectin Level
Adiponectin levels increased in the DHEA + CHI group after treatment.
Significant amelioration
Improvement in Estrous Cycle
The estrous cycle became more regular in the DHEA + CHI group compared to the DHEA group.